Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.36 |
| ▸ | TLR4 | O00206 | 7/20 | 0.33 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7144653 | 0.94 | TLR4 (0.36) | TLR2TLR4MBOAT4 | |
| SCHEMBL7136893 | 0.93 | SLC5A1 (0.33) | TLR2TLR4TNFLMNAKMT2A | |
| SCHEMBL7136807 | 0.92 | TLR4 (0.34) | TLR2TLR4LMNAKMT2A | |
| SCHEMBL7136812 | 0.92 | TLR4 (0.34) | TLR2TLR4LMNAKMT2A | |
| SCHEMBL7136889 | 0.87 | SLC5A1 (0.36) | TLR4 | |
| SCHEMBL2313871 | 0.86 | TLR4 (0.41) | TLR2TLR4TNFLMNAKMT2A | |
| SCHEMBL7133789 | 0.86 | TLR4 (0.34) | TLR4 | |
| SCHEMBL7133793 | 0.86 | TLR4 (0.34) | TLR4 | |
| SCHEMBL7141779 | 0.84 | TLR4 (0.36) | TLR4TNFLMNAKMT2A | |
| SCHEMBL7141782 | 0.84 | TLR4 (0.36) | TLR4TNFLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6511965-B2 | For therapy and prophylaxis of inflammatory disorders, autoimmune diseases or septicemia | SANKYO COMPANY, LIMITED (JP) | 2003-01-28 | — | — | US | disclosed |
| US-20020161221-A1 | Ether type lipid a 1-carboxylic acid analogs | SANKYO COMPANY, LIMITED (JP) | 2002-10-31 | — | — | US | disclosed |
| EP-1152007-A1 | ETHER TYPE LIPID A1-CARBOXYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161221-A1 | Ether type lipid a 1-carboxylic acid analogs | MSR1, ELOVL1, FFAR1 | TLR2 165/4885TLR4 296/4885TNF 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.